Werewolf Therapeutics is a biopharmaceutical company, engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Co. is utilizing its proprietary PREDATOR platform to design molecules that stimulate both adaptive and innate immunity with the aim of addressing the limitations of conventional proinflammatory immune therapies. Co.'s molecules, which it refers to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Co.'s product candidates, WTX-124 and WTX-330, are delivered, activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of solid tumors. We show 13 historical shares outstanding datapoints in our coverage of HOWL's shares outstanding history.
Understanding the changing numbers of HOWL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HOWL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HOWL by allowing them to research HOWL shares outstanding history
as well as any other stock in our coverage universe. |
Free HOWL Email Alerts:
Video: Shares Outstanding Importance
